Published in Stem Cell Reports on May 09, 2017
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 28.73
Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood (2004) 13.79
T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol (2007) 12.20
Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity (2002) 9.29
Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell (2009) 7.62
Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A (2003) 7.41
Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood (2004) 6.02
Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol (2011) 5.05
Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol (1999) 4.97
Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol (2005) 4.57
Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood (2005) 4.10
Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood (2004) 4.04
Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res (2011) 3.73
Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood (2006) 3.52
Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell (2012) 2.87
Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells (2009) 2.68
Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A (2005) 2.49
IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci U S A (2007) 2.46
Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev (2004) 2.30
Innocuous IFNgamma induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production. J Exp Med (2008) 2.28
Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes (2008) 2.25
Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin (2013) 2.10
Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol (2014) 1.90
The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood (2008) 1.75
The role of macrophages in T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Exp Med (1999) 1.58
Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proc Natl Acad Sci U S A (2011) 1.58
Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy. Microvasc Res (2009) 1.51
Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood (2008) 1.39
Experimental autoimmune uveoretinitis in the rat and mouse. Curr Protoc Immunol (2003) 1.32
Risk of tumorigenicity in mesenchymal stromal cell-based therapies--bridging scientific observations and regulatory viewpoints. Cytotherapy (2013) 1.27
Dendritic cells from nonobese diabetic mice exhibit a defect in NF-kappa B regulation due to a hyperactive I kappa B kinase. J Immunol (2001) 1.26
Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood (2008) 1.26
Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes (2010) 1.24
Exosomes for drug delivery - a novel application for the mesenchymal stem cell. Biotechnol Adv (2012) 1.23
Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species. Stem Cell Res Ther (2015) 1.21
Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs. Nat Commun (2015) 1.20
TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo. Proc Natl Acad Sci U S A (2014) 1.19
Th1 and Th2 lymphocytes in autoimmune disease. Crit Rev Immunol (2005) 1.19
TSG-6 produced by hMSCs delays the onset of autoimmune diabetes by suppressing Th1 development and enhancing tolerogenicity. Diabetes (2013) 1.13
Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway. PLoS One (2013) 1.08
Therapeutic factors secreted by mesenchymal stromal cells and tissue repair. J Cell Biochem (2011) 1.05
Extracellular Vesicles Improve Post-Stroke Neuroregeneration and Prevent Postischemic Immunosuppression. Stem Cells Transl Med (2015) 1.02
Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications. Mol Ther (2015) 1.02
Allo-reactivity of mesenchymal stem cells in rhesus macaques is dose and haplotype dependent and limits durable cell engraftment in vivo. PLoS One (2014) 1.00
Inhibition of immune synapse by altered dendritic cell actin distribution: a new pathway of mesenchymal stem cell immune regulation. J Immunol (2010) 0.97
Tissue factor triggers procoagulation in transplanted mesenchymal stem cells leading to thromboembolism. Biochem Biophys Res Commun (2013) 0.97
Extracellular vesicles for drug delivery. Adv Drug Deliv Rev (2016) 0.93
Human mesenchymal stem cells and renal tubular epithelial cells differentially influence monocyte-derived dendritic cell differentiation and maturation. Cell Immunol (2010) 0.93
Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies. Stem Cells Transl Med (2015) 0.92
Chromatographically isolated CD63+CD81+ extracellular vesicles from mesenchymal stromal cells rescue cognitive impairments after TBI. Proc Natl Acad Sci U S A (2015) 0.90
The Dark Side of the Force - Constraints and Complications of Cell Therapies for Stroke. Front Neurol (2015) 0.89
Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy. Yonsei Med J (2013) 0.88
Therapeutic Potential of Multipotent Mesenchymal Stromal Cells and Their Extracellular Vesicles. Hum Gene Ther (2015) 0.87
SJL and NOD macrophages are uniquely characterized by genetically programmed, elevated expression of the IL-12(p40) gene, suggesting a conserved pathway for the induction of organ-specific autoimmunity. J Leukoc Biol (2001) 0.87
Mesenchymal stem/stromal cells precondition lung monocytes/macrophages to produce tolerance against allo- and autoimmunity in the eye. Proc Natl Acad Sci U S A (2015) 0.86
The Role of Microvesicles Derived from Mesenchymal Stem Cells in Lung Diseases. Biomed Res Int (2015) 0.82
Mesenchymal stem/stromal cells protect against autoimmunity via CCL2-dependent recruitment of myeloid-derived suppressor cells. J Immunol (2015) 0.81
Mesenchymal stromal cell-derived extracellular vesicles rescue radiation damage to murine marrow hematopoietic cells. Leukemia (2016) 0.80
Mesenchymal Stromal Cell-Derived Extracellular Vesicles Protect the Fetal Brain After Hypoxia-Ischemia. Stem Cells Transl Med (2016) 0.79
Mesenchymal stem cell derived secretome and extracellular vesicles for acute lung injury and other inflammatory lung diseases. Expert Opin Biol Ther (2016) 0.79
Intraperitoneal infusion of mesenchymal stem/stromal cells prevents experimental autoimmune uveitis in mice. Mediators Inflamm (2014) 0.77
Interleukin-10: An Immune-Activating Cytokine in Cancer Immunotherapy. J Clin Oncol (2016) 0.76